Drug × Cancer matrix

Each row is a drug, each column a cancer subtype. Cells show the strongest known association for that drug in that cancer: approved clinical trial or blank. The repositionable flag means the drug appears as a synthetic-lethal repositioning candidate in cansar; it’s gene-level, not cancer-level.

Cancer key
GBM — Glioblastoma (CNS astrocytoma grade IV) LUAD — Lung adenocarcinoma SCLC — Small cell lung carcinoma LUSC — Lung squamous cell carcinoma OAC — Oesophageal adenocarcinoma OSCC — Oesophageal squamous cell carcinoma PDAC — Pancreatic ductal adenocarcinoma
Clear
Showing 20 of 20 matching drugs for CHURC1-FNTB — including drugs targeting any of its 3 synthetic-lethal partners , sorted by total cancer coverage.
Drug Target Relationship GBM LUAD SCLC LUSC OAC OSCC PDAC Reposition #cancers
adagrasib KRAS SSL via KRAS yes 2
afatinib EGFR SSL via EGFR yes 2
dacomitinib EGFR SSL via EGFR yes 2
erlotinib EGFR SSL via EGFR yes 2
gefitinib EGFR SSL via EGFR yes 2
sotorasib KRAS SSL via KRAS yes 2
lazertinib and amivantamab EGFR SSL via EGFR 1
osimertinib EGFR SSL via EGFR yes 1
afatinib dimaleate EGFR SSL via EGFR yes 0
cetuximab EGFR SSL via EGFR yes 0
erlotinib hydrochloride EGFR SSL via EGFR yes 0
lapatinib EGFR SSL via EGFR yes 0
lapatinib ditosylate EGFR SSL via EGFR yes 0
necitumumab EGFR SSL via EGFR yes 0
neratinib EGFR SSL via EGFR yes 0
neratinib maleate EGFR SSL via EGFR yes 0
osimertinib mesylate EGFR SSL via EGFR yes 0
panitumumab EGFR SSL via EGFR yes 0
regorafenib EGFR SSL via EGFR yes 0
vandetanib EGFR SSL via EGFR yes 0
Approval data manually curated from National Cancer Institute and Drugs@FDA. Clinical trials from ClinicalTrials.gov. Repositionable list from cansar.ai.